Journal
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
Volume 6, Issue 3, Pages 311-323Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157489211796957757
Keywords
Chemotherapy; death domain; death effector domain; DISC; FADD; c-FLIP; scaffold; TRAIL; TRAIL-R4
Categories
Funding
- Conseil Regional de Bourgogne
- INCa (Institut National du Cancer)
- Cancceropole Grand-Est
- ANR (Agence Nationale de la Recherche [ANR-06-JCJC-0103, 07-PCV-0031]
- European Community
- Ministry of Research and Education
- ARC (Association pour la Recherche sur le Cancer)
- INCa
- Agence Nationale de la Recherche (ANR) [ANR-06-JCJC-0103] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
